Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

BMS Reports ‘Clinically Meaningful’ PFS Benefit In Topline Confirmatory Results For Krazati

01 Apr 2024

• By Alaric DeArment

• Source: Shutterstock

Related Content

US FDA In No Hurry To Withdraw Amgen’s Lumakras Despite Negative Adcomm Vote On Confirmatory Trial Results

05 Oct 2023

BMS Looks To Expand Its Oncology Reach With Mirati Buyout

09 Oct 2023

Amgen Wins World-First Lumakras Approval, Faces Challenge Of COVID-Era Launch

29 May 2021

Mirati’s Krazati Is Second KRAS Inhibitor To Market, But At Higher Price

14 Dec 2022

Related Companies

Bristol Myers Squibb Company

Amgen, Inc.

Merck & Co., Inc.

Additional Topics

Clinical Trials Business Strategies Research & Development Cancer BioPharmaceutical

More from Clinical Trials

More from R&D

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.